HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment
Acta Diabetologica · 2025
DOI: 10.1007/s00592-025-02459-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2025. Verfasst von Yuta Yamamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayam…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Hyperglycemia, Diabetes Mellitus, Experimental. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noster Inc.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The oral administration of linoleic acid immediately before glucose tolerance test (OGTT) ameliorated postprandial hyperglycemia via GPR120 pathway in normal and type 1 diabetes (T1DM) rats. Linoleic acid could promote inflammatory mediators, but 10-hydroxy- cis -12-octadecenoic acid (HYA) converted from linoleic acid by Lactobacillus plantarum has higher GPR120 agonistic activity without promoting inflammatory mediators. This study examined whether the oral-administration of HYA immediately before OGTT also ameliorated the postprandial hyperglycemia in normal rats and T1DM rats injected with bolus insulin.
Methods
Normal and T1DM male Sprague-Dawley rats received HYA immediately before OGTT. Other T1DM rats were given HYA and Humulin R immediately before OGTT. We measured the concentration of glucose, insulin, glucagon-like peptide 1 (GLP-1) and cholecystokinin in blood before and after OGTT. We also measured the amount of glucose in the gastric tract after OGTT, and the amount of uptake of methyl-α-D-glucopyranoside in CACO-2 cells.
Results
Postprandial hyperglycemia was ameliorated by HYA in normal rats, and the postprandial blood glucose levels were slowly elevated by HYA in the T1DM model rats. HYA partially inhibited the uptake of methyl-α-D-glucopyranoside in CACO-2 cells. HYA slowed gastric motility and increased the plasma GLP-1 and cholecystokinin levels in normal rats. HYA also ameliorated the postprandial hyperglycemia in T1DM rats given bolus insulin.
Conclusion
Oral administration of HYA immediately before OGTT ameliorated postprandial hyperglycemia through inhibition of glucose absorption and slowing of gastric motility in normal rats. Furthermore, this beneficial effect of HYA was also revealed in T1DM rats injected with bolus insulin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. yuta-y@wakayama-med.ac.jp.
- Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
- Department of Anatomy and Cell Biology, Graduate School of Medical and Pharmaceutical Sciences, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
- Noster Inc., Kyoto, Japan.
Förderung
- Noster Inc
Zitieren
APA
Yamamoto, Y., Narumi, K., Yamagishi, N., Yonejima, Y., Iseki, K., Kobayashi, M., & Kanai, Y. (2025). HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02459-6
Vancouver
Yamamoto Y, Narumi K, Yamagishi N, Yonejima Y, Iseki K, Kobayashi M, et al. HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment. Acta Diabetologica. 2025. doi:10.1007/s00592-025-02459-6
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Yuta and Narumi, Katsuya and Yamagishi, Naoko and Yonejima, Yasunori and Iseki, Ken and Kobayashi, Masaki and Kanai, Yoshimitsu},
title = {HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment},
journal = {Acta Diabetologica},
year = {2025},
doi = {10.1007/s00592-025-02459-6}
}
EUVIMED